Establishment of humanised xenograft models as
lung metastasis
mouse model
osteosarcoma
xenograft
Journal
Immunotherapy advances
ISSN: 2732-4303
Titre abrégé: Immunother Adv
Pays: England
ID NLM: 101776979
Informations de publication
Date de publication:
2024
2024
Historique:
received:
24
09
2023
accepted:
27
03
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
epublish
Résumé
Humanised xenograft models and cancer cell lines are widely used for preclinical drug evaluation, biological studies, and targeted therapy strategies in cancer research. A humanised mouse model is a laboratory mouse that has been genetically modified to contain specific human genes, cells, or tissues. By introducing human-specific elements into rodents, researchers can create a more accurate representation of human physiological and pathological processes. Lacking an appropriate animal model for osteosarcoma (OS), hindered understanding of underlying mechanisms in OS metastasis progression. Markedly, metastasis influences the prognosis and treatment of osteosarcoma. Gaining insight into the mechanisms and occurrences of metastasis could potentially facilitate oncologists in improving therapies. Hence, it is important to develop a lung metastatic OS model to study the basic biology of its progression. This study has established a tumour-bearing mouse model using HOS-143B cell line which was injected into male NOD.SCID gamma (NSG) mice at two locations; intramuscularly (hind leg) and subcutaneously (back) respectively. The primary and metastatic tumour size was monitored by palpating the area of tumour induced and quantified using digital calliper. H&E staining was performed by pathologist to confirm metastasis. Our results showed that mice injected with 1 million cancer cells were unable to produce tumours. Meanwhile, mice injected with three million cancer cells showed tumour development and lung metastasis after 25 days of cancer cell inoculation. In conclusion, this study has successfully established a lung metastatic OS mouse model that could be useful for biological studies of OS. These findings imply that this model is essential for safety and efficacy before clinical trials, accelerate the translation from basic research to therapeutic applications.
Identifiants
pubmed: 38826586
doi: 10.1093/immadv/ltae002
pii: ltae002
pmc: PMC11143482
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ltae002Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Immunology.
Déclaration de conflit d'intérêts
The authors declare that there are no potential conflicts of interest regarding this study.